Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 8/20 | 0.42 |
| ▸ | MAOB | P27338 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | PRF1 | P14222 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.39 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.39 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20570609 | 0.93 | CYP3A4 (0.47) | CYP3A4MAPTLMNAGAAMAOA | |
| SCHEMBL854481 | 0.84 | CYP3A4 (0.53) | CYP3A4MAPTLMNAGAAMAOA | |
| SCHEMBL855514 | 0.84 | CYP3A4 (0.53) | CYP3A4MAPTLMNAGAAMAOA | |
| SCHEMBL854665 | 0.78 | CYP3A4 (0.47) | CYP3A4MAPTLMNAGAAMAOA | |
| SCHEMBL32666728 | 0.78 | CYP3A4 (0.47) | CYP3A4MAPTLMNAGAAMAOA | |
| SCHEMBL2732842 | 0.78 | CYP3A4 (0.51) | CYP3A4MAPTLMNAGAAMAOA | |
| SCHEMBL30591654 | 0.78 | CYP3A4 (0.47) | CYP3A4MAPTLMNAGAAMAOA | |
| SCHEMBL21776729 | 0.78 | MAPT (0.53) | CYP3A4MAPTLMNAGAAMAOA | |
| SCHEMBL2729424 | 0.78 | CYP3A4 (0.47) | CYP3A4MAPTLMNAGAAMAOA | |
| SCHEMBL27094979 | 0.78 | CYP3A4 (0.47) | CYP3A4MAPTLMNAGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116457344-B | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4630414-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025061148-A1 | HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| WO-2024121256-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-06-13 | — | — | WO | disclosed |
| CN-116457344-A | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4188373-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | Captor Therapeutics S.A. (PL) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022029138-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2022-02-10 | — | — | WO | disclosed |
| US-8604221-B2 | Production method of halogen-substituted phthalide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120142946-A1 | PRODUCTION METHOD OF HALOGEN-SUBSTITUTED PHTHALIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2433933-A1 | PRODUCTION METHOD OF HALOGEN-SUBSTITUTED PHTHALIDE | Sumitomo Chemical Company, Limited (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | MMP2, PSME2, PSME1 | CYP3A4 2913/4885MAPT 3551/4885LMNA 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.